Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
In a breakthrough that offers new hope for the containment of influenza outbreaks, an Australian biotechnology company has isolated a natural extract from seaweed which has been shown to inhibit the H1N1 virus.
Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it plans to initiate patient recruitment for a cancer immunotherapy study by year end. The pilot study seeks to demonstrate an improved immune function in cancer patients as a result of the Aethlon Hemopurifier removing tumor-secreted exosomes from the circulatory system.
MicroStockProfit.com announces an investment report featuring Vical Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
A study of emergency department activity before and during the H1N1 influenza pandemic highlights the role public fear can play in unnecessarily straining medical facilities and will aid in ongoing preparations for public health emergencies, according to the authors.
More than 99 percent of specimens tested for influenza were positive for H1N1 over approximately the past 11 months, according to a report released today from Quest Diagnostics Incorporated ( DGX). The Quest Diagnostics Health Trends™ Report suggests that H1N1 "crowded out" other influenza viruses to be the dominant flu virus of the 2009-2010 flu season.
Children hospitalized with pandemic H1N1 influenza in 2009 were older and more likely to have underlying medical conditions than children hospitalized with seasonal influenza during prior flu seasons, according to a study to be presented Tuesday, May 4 at the Pediatric Academic Societies annual meeting in Vancouver, British Columbia, Canada.
The United States Government in an announcement on Monday revealed that the U.S. still has 71 million doses of unused H1N1 swine flu vaccine but there is still time left before it is wasted. They have urged the providers to keep the vaccines and continue to supply them to people until pharmaceutical manufacturers start distributing seasonal vaccine for the coming influenza season in the autumn.
BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
Initial reports linking seasonal flu vaccine and getting swine flu or H1N1 flu emerged September 2009 in Canada. In spring 2009 many people who acquired pandemic H1N1 flu had been initially vaccinated with seasonal flu vaccine. This triggered four additional studies in Canada to explore the link further. The studies included 2,700 patients with or without H1N1. The first of the studies showed a surprising 68 percent rise of risk of development of H1N1 flu in those vaccinated with seasonal flu shot. The other 3 studies showed increase of risk of H1N1 flu by 1.4 to 1.5 times with the original flu shot.
GeNOsys, Inc. today announced they are sponsoring a Phase I safety trial in collaboration with Nitric Solutions Inc. GeNOsys will be testing their patented nitric oxide generator and nitric oxide producing formula for safety and effectiveness in treating disease. In a parallel study Nitric Solutions will be testing the efficacy of their prophilactic nitric oxide producing formula Nitrisol.
BioSante Pharmaceuticals, Inc. will present a BioSante cancer vaccine portfolio update at the BIO International Convention, which will take place May 3-6 in Chicago, Illinois.
Amerigroup Corporation today announced that net income for the first quarter of 2010 was $42.2 million, or $0.82 per diluted share, versus $40.2 million, or $0.79 per diluted share, for the fourth quarter of 2009.
More Americans were vaccinated against seasonal flu during the 2009-10 season (40 percent of eligible population) than during the previous flu season (33 percent of eligible population), according to a report by the Centers for Disease Control and Prevention.
Practicing non-pharmaceutical interventions such as hand-washing and mouth covering may help limit the transmission of the pandemic flu, but more research on these measures is critical according to a new study appearing in the May issue of AJIC: American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology, Inc.
Novavax, Inc. reported today that its trivalent seasonal influenza virus-like-particle (VLP)-based vaccine candidate was safe and immunogenic against the 2009-2010 seasonal influenza virus strains in older adults 60 years or higher in age.
West Pharmaceutical Services, Inc. today announced its results for the first quarter of 2010.
A clinical trial of 406 subjects 50 years of age and older who were hospitalized with pneumonia showed a one-day reduction in the length of hospital stay in those patients who received osteopathic manipulative treatment (OMT) in addition to conventional medical care when compared to patients who received only conventional medical care. A per protocol analysis also showed a significant reduction in the duration of intravenous antibiotics and in respiratory failure or death in the group that received OMT when compare to the conventional care only group.
Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.
After the seasonal flu vaccines caused over 250 cases of fever, vomiting and convulsions and one reported death in under-fives there has been intense investigations to detect the cause. Further vaccinations were stopped last Friday.
Discovery Laboratories, Inc., a biotechnology company developing its novel synthetic surfactant and aerosol technologies for respiratory diseases, today provides an update on Surfaxin® and key pipeline and business initiatives and reports financial results for the first quarter ended March 31, 2010.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.